KALRAY
7.2.2024 17:41:31 CET | Business Wire | Press release
Kalray (Euronext Growth Paris: ALKAL), a leader in hardware and software technologies dedicated to data management and data intensive processing from cloud to edge, today announced a strategic collaboration with Arm to deliver ultra-high performance data processing and AI capabilities across a broad set of applications, leveraging Kalray’s industry leading data processing unit (DPU) technology and Arm’s robust partner ecosystem.
The ever-increasing demand for advanced data processing and AI capabilities has become a cornerstone of modern applications, ranging from storage and networking appliances to data center servers and edge computing, such as smart vision systems or telecom solutions.
This diverse application spectrum requires innovative solutions that can manage increasing data and processing requirements while delivering peak performance and high levels of power and cost efficiency. The combination of Kalray’s advanced AI and data processing acceleration capabilities paired with the broad Arm partner ecosystem will make high performance solutions for hardware and software developers across global enterprises more accessible.
In practical terms, this collaboration translates into Kalray integrating Arm® Neoverse™ Coherent Mesh Network (CMN) interconnect technology into Kalray’s next generation data processing and AI accelerator chiplet (code named “Dolomites”). This will enable the connection of Kalray’s DPU to Arm-based chiplets1 using the Arm CMN interconnect, delivered in the same package. It’s an innovative approach that optimizes flexibility, performance, power consumption, and cost efficiency; and it’s aimed at opening new horizons for a wide ecosystem of software developers, enabling them to leverage Kalray’s advanced processor capabilities to drive innovation across multitudes of applications.
“We couldn’t be more thrilled to collaborate with Arm and to bring the unique AI and data intensive processing capabilities offered by our DPU technology to the global Arm ecosystem,” said Eric Baissus, Kalray CEO. “This is a visionary step towards shaping the future of AI processing, making it more accessible, efficient, and powerful for a wider range of applications."
“AI is becoming integral to the entire compute infrastructure, driving an insatiable demand for more data and more computing power,” said Dermot O’Driscoll, vice president of product solutions, Infrastructure Line of Business, Arm. “By leveraging Arm’s CMN interconnect technology, Kalray is making its data acceleration solutions accessible across Arm’s global ecosystem and we look forward to this collaboration sparking new and impactful innovation for the era of AI.”
“This announcement maps to our expectation of increasing data processing solutions that address the expanding set of AI workloads,” said Howard Holton, chief technology officer, GigaOm. “The combination of Arm’s unique ecosystem and Kalray’s innovative DPU technology has the potential to bring the best of two worlds together at a time when the market has an insatiable appetite for data intensive processing.”
ABOUT KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data-centric computing markets, from cloud to edge.
Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented data processing unit (DPU) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, media & entertainment, life sciences, scientific research, edge computing, automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
ABOUT ARM
Arm technology is building the future of computing. Its energy-efficient processor designs and software platforms have enabled advanced computing in more than 270 billion chips and its technologies securely power products from the sensor to the smartphone and the supercomputer. Together with 1,000+ technology partners, Arm is enabling artificial intelligence to work everywhere, and in cybersecurity, it is delivering the foundation for trust in the digital world – from chip to cloud. The future is being built on Arm.
1 A chiplet is a discrete unpackaged die that can be assembled into a package with other chiplets and assembled into a single processor chip. This new approach enables the development of processors that combine multiple chiplets, offering gains in flexibility and efficiency compared to traditional approaches.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207386465/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom